market access – Partners4Access

Is Italy a favourable market for Orphan Drugs? The latest OSSFOR Booklet paints a promising picture for the Italian landscape

BlogsBy partnersadmin March 26, 2021

By Andrea Bernardini, Analyst & Akshay Kumar, Partner Email: abernardini@partners4access.com akumar@partners4access.com On the 12th of February the Orphan Drugs Observatory and the Italian Society of Hospital Pharmacy and Pharmaceutical Services for Healthcare (OSSFOR) have produced the 5th Report on orphan drugs receiving Innovative Status by AIFA in Italy. Although AIFA’s algorithm for assigning innovation status…

P4A to host webinar on EU Market Access developments in 2021

NewsBy partnersadmin January 8, 2021

Leading specialist market access consultancy Partners4Access (P4A) is to host a free webinar to share insights on key 2021 trends in market access for pharma/biotech manufacturers. The webinar titled ` EU Market Access 2021:What’s in store for Orphan Drugs and ATMPs?’ will be conducted by educational webinars provider Xtalks and will be held on Wednesday,…

P4A To Discuss Early Access Strategy Insights In New Webinar

NewsBy partnersadmin September 14, 2020

Leading specialist market access consultancy Partners4Access (P4A) is to host a free webinar that will share insights on key considerations for pharma/biotech manufacturers on early access program strategy and implementation. The webinar titled ` Early Access Programs in Europe: ‘A Friend or a Foe’ will be conducted by educational webinars provider Xtalks and will be…

Zolgensma’s ‘Day One’ access scheme – can Novartis’s early access plan succeed?

BlogsBy partnersadmin May 22, 2020

By Max Rex, Associate Consultant Email: mrex@partners4access.com Zolgensma, Novartis’s blockbuster gene therapy for the treatment of spinal muscular atrophy (SMA), was officially given the green light by the European Medicines Agency on 19th May. The therapy has previously been approved in the US and Japan, and has already generated sales of over $500 million dollars…

Partners4Access sponsors World Orphan Drug Congress USA 2019

NewsBy partnersadmin April 8, 2019

Partners4Access has announced their gold sponsorship of the biotech industry conference World Orphan Drug Congress (WODC) USA. The event will take place at The Gaylord National Harbor Hotel in Oxon Hill, Maryland between April 10-12, 2019. The P4A team will be involved in three main segments of WODC: Sophie Schmitz, Managing Partner will be moderating…

Innovative Access Agreements: A potential payer solution for Cell & Gene Therapies

Publications/White PapersBy partnersadmin September 21, 2018

A US and EU perspective By Daniele Severi Bruni & Sophie Schmitz What’s the idea? Payer concerns over increasing cost of therapies and uncertainty of clinical data has led to a growing interest in market access tools. Experts Daniele Severi Bruni partner at MKO and Sophie Schmitz from Partners4Access discuss this potential payer solution for…

Seven months to Brexit, does the biopharma industry have the tools to be ready?

BlogsBy partnersadmin August 7, 2018

Everything you need to know about the latest Brexit White Paper By Joanna Fernandes, Analyst Email: jfernandes@partners4access.com As the countdown to Brexit draws near, a flurry of activities has emerged from the UK government, the EU and the pharma/biotech industry. But central to the conversation is the recent white paper released by the UK government…

Partners4Access expands top leadership with new appointment

NewsBy Nick April 17, 2018

Partners4Access has announced the appointment of Alison Kneen as Vice President of International Operations to lead its rapidly expanding Market Access Orphan Drug Specialist team. Alison brings extensive international market access experience built over the last 27 years from previous roles with IQVIA; Principal and Head of Market Access Strategic Consulting, as well as during…

Tag Archives: market access